Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Coegin Pharma AB: BioStock: Coegin Pharma takes key steps for growth during Q3

Coegin Pharma
Read the release

Q3 was an active quarter for Coegin Pharma and its pursuit to address a large unmet medical need in cancer and chronic inflammatory diseases. Highlighted in the company's interim report are the initiation of the COAK study with AVX001 gel in actinic keratosis patients, the merger with Swedish biotech Follicum, and the development of a new candidate for the treatment of leukaemia and potentially other cancers.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/coegin-pharma-takes-key-steps-for-growth-during-q3/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.